Surgery Doctors in Juneau, AK Accepting Medicare

5 Surgery doctors found. Showing 1 - 5

Dr. Allan G Schlicht, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2221 Jordan Ave, Juneau, AK 99801 Phone: 907-789-1277    Fax: 907-789-3362

William M Palmer, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3268 Hospital Dr, Ste E, Juneau, AK 99801 Phone: 907-586-1895    Fax: 907-586-2595

Dr. Pamela A Gruchacz, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3225 Hospital Drive, Suite 101a, Juneau, AK 99801 Phone: 907-796-8700    Fax: 907-796-8710

Jennifer Elise Schmidt, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3225 Hospital Dr Unit 101a, Juneau, AK 99801 Phone: 907-796-8700

Benjamin Adam Miller, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 3268 Hospital Dr Ste A, Juneau, AK 99801 Phone: 907-796-8700    Fax: 907-796-8710

News Archive

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.

VOA News examines international HIV/AIDS implementers meeting

VOA News examines the 2009 HIV/AIDS Implementers Meeting in Windhoek, Namibia, which recently brought together 1,500 people from 55 countries to compare notes on HIV/AIDS programs around the world. The article features comments by Assistant U.S. Global AIDS Coordinator Michele Moloney-Kitts who attended and shared some of her experiences from the meeting.

VisionWeb achieves 100,000,000 online order milestone

VisionWeb, the premier provider of cloud-based technology services to the optical industry, announced that they have reached 100,000,000 online orders placed through the VisionWeb online ordering portal.

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

Read more Medical News

› Verified 4 days ago